The company has reported the sales of 83.6 billion Swiss francs.
Paul Bulcke, Nestlé CEO,
We delivered good performance, top and bottom line, in both emerging and developed markets in 2011. It was a challenging year, and we do not expect 2012 to be any easier. We have continued to invest for the future and strengthen our capabilities across the world. We have established new partnerships in China. Nestlé Health Science has got off to a good start. Our innovation is creating opportunities in all categories, whether bringing new consumers to our brands in emerging markets, or building on our consumers’ engagement with our brands in the developed world. Our people are aligned behind our strategic roadmap, which is as relevant in today’s new reality as ever, to drive sustainable performance improvement. We are therefore well positioned in 2012 to deliver the Nestlé Model of organic growth between 5% and 6% as well as an improved margin and underlying earnings per share in constant currencies.The company has reported 5% of organic growth in Europe and 6.4% in the Americas. There is more growth of 13.1% in the Asia, Oceania and Africa.